Email this article 
EVIDENCE-BASED TREATMENT OF REFRACTORY CHRONIC URTICARIA
- Authors: Danilycheva IV1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 11, No 6 (2014)
- Pages: 63-69
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2014
- URL: https://rusalljournal.ru/raj/article/view/535
- DOI: https://doi.org/10.36691/RJA535
- ID: 535
Cite item
Open Access
Access granted
Abstract
Despite advances in understanding of mechanisms of development of hives, many patients and their physicians remain unsatisfied results of treatment, lack of control of the disease. Now treatment of patients with the chronic urticarial has landmark character. The new indication for omalizumab was registered in Russia in 2014, giving the chance to achieve the control on a refractory form of urticaria. Omalizumab demonstrated rapid and beneficial effects on the signs and symptoms of chronic spontaneous urticaria torpid to H1blockers in the numerous studies.
Keywords
Full Text
About the authors
I V Danilycheva
Institute of Immunology
Email: ivdanilycheva@mail.ru
Moscow, Russia
References
- Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. GA2LEN task forse report. Allergy. 2011, v. 66, p. 317-330.
- Roger W., Fox M.D. Chronic urticaria: mechanism and treatment. Allergy and Asthma Proc. 2001, v. 22, p. 97-100.
- Голубчикова Р.Н., Данилычева И.В. Хроническая идиопатическая крапивница. Диагностическая проблема. Рос. Аллергол. Журн. 2012, № 3, c. 3-6.
- Zuberbier T., Aberer W., Asero R. et al. EAACI/GA2LEN/ EDF/WAO urticaria guidelines for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p. 868-887.
- Makris M., Maurer M., Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin. Pharmacother. 2013, v. 14, p. 2511-2519.
- Maurer M., Magerl M., Metz M., Zuberbier T Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J. Dtsch. Dermatol. Ges. 2013, v. 11, p. 971-978.
- Ваганова О.А., Ефремова Т.А., Миронов А.Н. и соавт. Направления совершенствования лекарственных препаратов моноклональных антител. Ведомости Научного центра экспертизы средств медицинского применения. 2014, № 1, c. 32-39.
- Chamow S. FcFusion Proteins: A Growing. Class of Therapeutics. Available from: http://www.austropainterconvention. at/congress/esact2011_abstract/downloads/ESACT%20 Workshop%20C%20Fusion%20Proteins.pdf.
- Metz M., Ohanyan Т., Church M.K. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
- Bousquet J., Rabe K., Humbert M. et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med. 2007, v. 101, p.1483-1492.
- Holgate S., Buhl R., Bousquet J. et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir. Med. 2009, v. 103, p. 1098-1113.
- Spector S.L., Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann. Allergy Asthma Immunol. 2007, v. 99, p. 190-340.
- Kaplan A.P., Joseph K., Maykut R.J. et al. Treatment of chronic autoimmune urticaria with omalizumab. J. Allergy Clin. Immunol. 2008, v. 122, p. 569-573.
- Gober L.M., Sterba P.M., Eckman J.A., Saini S.S. Effect of Anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients. J. Allergy Clin. Immunol. 2008, v. 121, p. 121-147.
- Magerl M., Staubach P., Altrichter S. et al. Effective treatment of therapy resistant chronic spontaneous urticaria with omalizumab. J. Allergy Clin. Immunol. 2010, v. 126, p. 665-666.
- Groffik A., Mitzel-Kaoukhov H., Magerl M. et al. Omalizumab: an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy. 2011, v. 66, p. 303-305.
- Maurer M., Altrichter S., Bieber T et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol. 2011, v. 128, p. 202-209.
- Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, v. 128, p. 567-573.
- Maurer M., Rosen К.Е., Hsieh H.J. et al.Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368, p. 924-935.
- Kaplan A., Ledford D., Ashby M. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 2013, v. 132, p. 101-109.
- Lang D.M. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema/ Ann. Allergy Asthma Immunol. 2014, v. 112, p. 276-279.
- Shankar T., Petrov A. Rhinitis, sinusitis and upper airway disease. Omalizumab and hypersensitivity reactions. Curr. Opin. Allergy Clin. Immunol. 2013, v. 13, p. 19-24.
- Casale T.B., Bernstein I.L., Busse W.W. et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 1997, v. 100, p. 110-121.
- MacGlashan D., Bochner B.S., Adelman D.C. et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with antiIgEantibody. J. Immunol. 1997, v. 158, p. 1438-1445.
- MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J. Allergy Clin. Immunol. 2004, v. 114, p.1472-1474.
- Noga O., Hanf G., Brachmann I. et al. Effect of omalizumab treatment on peripheral eosinophil and Tlymphocyte function in patients with allergic asthma. J. Allergy Clin. Immunol. 2006, v. 117, p. 1493-1499.
Supplementary files
